CN111249189B - 一种注射型美容整形用面部填充剂组合物及其制备方法 - Google Patents
一种注射型美容整形用面部填充剂组合物及其制备方法 Download PDFInfo
- Publication number
- CN111249189B CN111249189B CN202010039494.XA CN202010039494A CN111249189B CN 111249189 B CN111249189 B CN 111249189B CN 202010039494 A CN202010039494 A CN 202010039494A CN 111249189 B CN111249189 B CN 111249189B
- Authority
- CN
- China
- Prior art keywords
- injection
- mass
- hyaluronic acid
- filler composition
- injectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000000945 filler Substances 0.000 title claims abstract description 48
- 230000001815 facial effect Effects 0.000 title claims abstract description 41
- 229920003023 plastic Polymers 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000002347 injection Methods 0.000 claims abstract description 108
- 239000007924 injection Substances 0.000 claims abstract description 108
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 66
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 66
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 66
- 239000000243 solution Substances 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 33
- 102000008186 Collagen Human genes 0.000 claims abstract description 31
- 108010035532 Collagen Proteins 0.000 claims abstract description 31
- 229920001436 collagen Polymers 0.000 claims abstract description 31
- 210000003491 skin Anatomy 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 30
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 29
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 29
- 239000002131 composite material Substances 0.000 claims abstract description 28
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 27
- 230000003796 beauty Effects 0.000 claims abstract description 18
- 238000002316 cosmetic surgery Methods 0.000 claims abstract description 15
- 230000001954 sterilising effect Effects 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000005303 weighing Methods 0.000 claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000008961 swelling Effects 0.000 claims abstract description 8
- 210000004207 dermis Anatomy 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 30
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 23
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 19
- 239000001263 FEMA 3042 Substances 0.000 claims description 19
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 19
- 229920002258 tannic acid Polymers 0.000 claims description 19
- 229940033123 tannic acid Drugs 0.000 claims description 19
- 235000015523 tannic acid Nutrition 0.000 claims description 19
- 239000003431 cross linking reagent Substances 0.000 claims description 18
- 235000020696 epimedium extract Nutrition 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 14
- 241001106477 Paeoniaceae Species 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 239000007795 chemical reaction product Substances 0.000 claims description 9
- 239000008055 phosphate buffer solution Substances 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 5
- 229960004194 lidocaine Drugs 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003831 articaine Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229960003976 etidocaine Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002409 mepivacaine Drugs 0.000 claims description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001896 pramocaine Drugs 0.000 claims description 2
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 208000005189 Embolism Diseases 0.000 abstract description 7
- 230000002792 vascular Effects 0.000 abstract description 6
- 238000004132 cross linking Methods 0.000 abstract description 4
- 239000011859 microparticle Substances 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- 206010040954 Skin wrinkling Diseases 0.000 description 23
- 230000037303 wrinkles Effects 0.000 description 21
- 229920001864 tannin Polymers 0.000 description 10
- 235000018553 tannin Nutrition 0.000 description 10
- 239000001648 tannin Substances 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 4
- 241000893536 Epimedium Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 235000018905 epimedium Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 244000236658 Paeonia lactiflora Species 0.000 description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000426 Microplastic Polymers 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Abstract
Description
红斑情况 | 水肿情况 | |
实施例一 | 无红斑 | 无水肿 |
实施例二 | 无红斑 | 无水肿 |
实施例三 | 无红斑 | 无水肿 |
实施例四 | 无红斑 | 无水肿 |
实施例五 | 无红斑 | 无水肿 |
对照组 | 出现少量红斑 | 出现水肿 |
注射前皱纹情况 | 注射48h后皱纹情况 | |
实施例一 | 6.1±0.1 | 3.1±0.1 |
实施例二 | 5.8±0.1 | 3.2±0.1 |
实施例三 | 5.2±0.1 | 3.6±0.1 |
实施例四 | 6.0±0.1 | 4.2±0.1 |
实施例五 | 5.7±0.1 | 3.9±0.1 |
对照组 | 5.5±0.1 | 4.8±0.1 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010039494.XA CN111249189B (zh) | 2020-01-15 | 2020-01-15 | 一种注射型美容整形用面部填充剂组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010039494.XA CN111249189B (zh) | 2020-01-15 | 2020-01-15 | 一种注射型美容整形用面部填充剂组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111249189A CN111249189A (zh) | 2020-06-09 |
CN111249189B true CN111249189B (zh) | 2021-07-23 |
Family
ID=70948736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010039494.XA Active CN111249189B (zh) | 2020-01-15 | 2020-01-15 | 一种注射型美容整形用面部填充剂组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111249189B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2744966C1 (ru) * | 2020-07-26 | 2021-03-17 | Светлана Алексеевна Зорькина | Способ коррекции дефектов кожи |
CN112057351B (zh) * | 2020-09-22 | 2023-01-24 | 西安诗莱梦特生物科技有限公司 | 透明质酸-羟丙基甲基纤维素复合水凝胶及其制备方法和应用 |
CN112618787B (zh) * | 2020-12-30 | 2022-11-04 | 广州小蛮腰医疗器械有限公司 | 一种皮下组织填充制剂及其制备方法和应用 |
CN113144288A (zh) * | 2021-04-26 | 2021-07-23 | 磐升瑞祥(山东)生物工程有限公司 | 一种复合多组分的胶原蛋白微乳填充剂及其制备方法 |
CN113603903B (zh) * | 2021-08-04 | 2023-10-10 | 上海曜爱生物科技有限公司 | 一种可填充用的丝素蛋白凝胶的制备及应用 |
CN113941027A (zh) * | 2021-10-21 | 2022-01-18 | 珠海美如初医疗美容有限公司 | 一种注射型美容整形用面部填充剂组合物凝胶及其制备方法 |
CN113952510A (zh) * | 2021-11-09 | 2022-01-21 | 无锡本物医疗器械有限公司 | 一种靶向注射型填充剂组合物及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8394782B2 (en) * | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
TWI716365B (zh) * | 2014-11-13 | 2021-01-21 | 德商梅茲製藥有限兩合公司 | 注射型真皮填充劑組合物及其套組、製備方法、與使用 |
CN108744054A (zh) * | 2018-06-15 | 2018-11-06 | 北京水元生生物科技有限公司 | 一种注射型美容整形用面部填充剂组合物凝胶及其制备方法 |
-
2020
- 2020-01-15 CN CN202010039494.XA patent/CN111249189B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111249189A (zh) | 2020-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111249189B (zh) | 一种注射型美容整形用面部填充剂组合物及其制备方法 | |
CN112402310A (zh) | 一种玻色因多肽抗皱眼霜及其制备方法 | |
CN107260626B (zh) | 一种具有长效保湿作用的组合物及其制备方法 | |
CN108578747A (zh) | 一种梯度透明质酸敷料及其制备方法 | |
CN108478453A (zh) | 玻尿酸面膜液及其制作方法 | |
CN108686255A (zh) | 一种预防疤痕形成的生物敷料及其制备方法 | |
CN104814901B (zh) | 一种预防妊娠纹凝胶及其制备方法 | |
CN102600494A (zh) | 一种多糖组合物及其制备方法和用途 | |
CN114948788B (zh) | 一种舒缓修护三重蛋白组合物及其应用 | |
CN112137951A (zh) | 一种强韧发丝修复头皮屏障的无硅油透明氨基酸洗发水及其制备方法 | |
CN111603433A (zh) | 一种婴幼儿用温和洗护用品及其制备方法 | |
KR102613845B1 (ko) | 천연물 유래의 피부개선용 화장조성물 | |
CN110721148A (zh) | 一种多方位提拉紧致多肽精华液及其制备方法 | |
EP2136771B1 (en) | Compositions containing n-acetylglucosamine for use in dermo-cosmetology and aesthetic medicine | |
KR101895037B1 (ko) | 스피큘을 포함하는 하이드로겔 조성물 및 이의 용도 | |
CN105749333B (zh) | 一种透明质酸医用敷料及其制备方法 | |
CN110368347A (zh) | 一种抗衰修复双层双色精华素及其制备方法 | |
CN114042027A (zh) | 一种具有敏感肌修护功效的组合物及其制备方法和应用 | |
CN112891280A (zh) | 含枸杞干细胞能够提升皮肤紧致度的组合物及其应用 | |
CN111358710A (zh) | 一种保湿舒缓阿胶面霜及其制备方法 | |
CN116725933A (zh) | 一种美白保湿修复面膜及其制备方法 | |
EP1949889A1 (en) | Fibroblast activator, method for activation of fibroblast, collagen synthesis promoter, method for promotion of collagen synthesis, skin aging-preventing agent, and method for prevention of aging of the skin | |
CN112773816B (zh) | 一种创面修复喷剂及其制备方法和应用 | |
CN114225117A (zh) | 一种含有交联葡聚糖的综合性面部填充剂及其制备方法 | |
CN112754981A (zh) | 一种促进胶原再生型制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240321 Address after: Room 101, 1st Floor, Building 11, No. 50 Huatuo Road, Daxing Biopharmaceutical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing 102629 Patentee after: Moge (Beijing) Biotechnology Co.,Ltd. Country or region after: Zhong Guo Address before: 150001 building 7, 45 Yanxing Road, Nangang District, Harbin City, Heilongjiang Province Patentee before: Chen Yong Country or region before: Zhong Guo |